论文部分内容阅读
伦敦皇家免费医院于1963年开始在慢性活动性肝炎病人中进行强的松龙治疗的前瞻性对照试验。44例随机分配到治疗组和对照组。治疗组每天服强的松龙15mg,治疗一直持续到病人无症状,肝功能试验恢复正常。44例中30例在医院门诊定期(每半年～一年一次)观察,13例由原转诊医生或医院治疗,1例于5年后失去联系。在24例死亡病人中,21例的死因可查,8例曾作尸检。21例作HB_sAg检查,均属阴性。1970年以前死亡病人虽未作此检查,但绝大多数为女性及英国人,故认为不可能携带乙型肝炎病毒。1963～1967年进入试验的病人,除1例外,至少已随访10年,应用皮质激素期限为1/2～13年(平均4.5年)。对照组中2例因复发而改用强的松龙治疗。
A prospective controlled trial of prednisolone in chronic active hepatitis patients started in 1963 by the Royal London Free Hospital. 44 cases were randomly assigned to treatment group and control group. Treatment group daily dose of prednisolone 15mg, treatment continued until the patient asymptomatic, liver function tests returned to normal. Of the 44 patients, 30 were regularly observed in the hospital (once every six months to once a year), 13 were treated by the original doctor or hospital, and one patient lost contact after 5 years. Of the 24 deaths, 21 were found dead and 8 were autopsy. 21 cases for HB_sAg examination, are negative. Although the death of patients before 1970 did not make this check, but the vast majority of female and British, it is considered impossible to carry the hepatitis B virus. Patients who entered the trial between 1963 and 1967, except for one, had been followed for at least 10 years and corticosteroids for a period of 1½ to 13 years (mean, 4.5 years). Two patients in the control group were treated with prednisolone because of recurrence.